Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial

Natalie Reizine, Everett E. Vokes, Ping Liu, Tien M. Truong, Rita Nanda, Gini F. Fleming, Daniel V.T. Catenacci, Alexander T. Pearson, Sandeep Parsad, Keith Danahey, Xander M. van Wijk, Kiang-Teck J. Yeo, Mark J. Ratain and Peter H. O’Donnell

Abstract

Background: Many cancer patients who receive chemotherapy experience adverse drug effects. Pharmacogenomics (PGx) promises to personalize chemotherapy drug dosing to maximize efficacy and safety. Fluoropyrimidines and irinotecan have well-known germline PGx associations. At our institution, we have delivered PGx clinical decision support (CDS) based on preemptively obtained genotyping results for a large number of non-oncology medications since 2012, but have not previously evaluated the utility of this strategy for patients initiating anti-cancer regimens. We hypothesize that providing oncologists with preemptive germline PGx information along with CDS will enable individualized dosing decisions and result in improved patient outcomes.

Methods: Patients with oncologic malignancies for whom fluoropyrimidine and/or irinotecan-inclusive therapy is being planned will be enrolled and randomly assigned to PGx and control arms. Patients will be genotyped in a clinical laboratory across panels that include actionable variants in *UGT1A1* and *DPYD*. For PGx arm patients, treating providers will be given access to the patient-specific PGx results with CDS prior to treatment initiation. In the control arm, genotyping will be deferred, and dosing will occur as per usual care. Co-primary endpoints are dose intensity deviation rate (the proportion of patients receiving dose modifications during the first treatment cycle), and grade ≥3 treatment-related toxicities throughout the treatment course. Additional study endpoints will include cumulative drug dose intensity, progression-free survival, dosing of additional PGx supportive medications, and patient-reported quality of life and understanding of PGx.

Discussion: Providing a platform of integrated germline PGx information may promote personalized chemotherapy dosing decisions and establish a new model of care to optimize oncology treatment planning.

Keywords: chemotherapy, fluoropyrimidines, genetic testing, irinotecan, pharmacogenomics, toxicity management

Received: 1 July 2020; revised manuscript accepted: 23 October 2020.
Fluoropyrimidines (5-fluouracil [5-FU], capecitabine) and irinotecan are commonly prescribed chemotherapies, with efficacy across a broad range of tumor types. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in fluoropyrimidine metabolism. Polymorphisms in the DPYD gene can result in enzyme deficiency leading to an increased risk of severe, sometimes fatal toxicities in up to 10% of patients. Allele frequencies of these variants vary among ethnic groups and confer different levels of predicted frequencies of these variants vary among ethnic groups. The potential application of germline PGx information offers an additional avenue for the delivery of personalized medicine in oncology.

The feasibility and safety of fluoropyrimidine genotype-guided dosing has now been demonstrated by several groups. Deenen et al. prospectively screened patients initiating fluoropyrimidine therapy for DPYD*2A; among >2000 patients screened, 22 patients were identified as *2A heterozygotes, and 18 preemptively received reduced fluoropyrimidine dosing (the other four did not receive a fluoropyrimidine). The incidence of severe toxicities (grade ≥3) among carriers was 28%, which compared very favorably with the observed toxicity of a historical cohort of patients with DYPD*2A variants who received full-dose fluoropyrimidines (grade ≥3 toxicity rate 78%), and with the concurrently treated group of patients who did not carry *2A and received full-dose fluoropyrimidines (23% grade ≥3 toxicity rate). Compared to the historical cohort of *2A carriers who received full dosing, the risk of drug-induced death was reduced from 10% to 0% in *2A carriers receiving reduced dosing. Furthermore, the average total treatment cost was modeled as being modestly lower with screening, even when including the screening costs for the entire population. Subsequently, Henricks et al. prospectively evaluated genotype-guided dosing that was extended to include four DPYD variants (*2A or c.1905+1G>A, c.2846A>T, *13 or c.1679T>G, and HapB3/c.1236G>A). Heterozygous variant allele carriers comprised 8% of all patients evaluated (85 of 1103 patients) and received initial chemotherapy dose reductions. The relative risk of severe fluoropyrimidine-related toxicity was reduced in all groups as compared to historical controls. Based on these and other data, the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends upfront dose reductions for carriers of these alleles. Finally, recent data have also demonstrated that the DPYD variant c.557A>G (rs115232898, p.Y186C), which is present in 3–5% of individuals with African ancestry, results in reduced functional DPD enzyme levels and is likewise associated with higher rates of fluoropyrimidine toxicity.

A number of studies (both observational and prospective) are ongoing to evaluate the impact of DPYD variant testing in cancer patients, albeit in a non-randomized fashion.

Similarly, the active metabolite of irinotecan, 7-Ethyl-10-hydroxycamptothecin (SN-38), is glucuronidated (inactivated) by the enzyme uridine diphosphate (UDP) glucuronosyltransferase family polypeptide A1, which is encoded by the UGT1A1 gene. The UGT1A1 gene has common thymine-adenine (TA) insertion/deletion polymorphisms in the promoter region, and some populations also manifest a missense variant in exon 1, either of which results in an altered risk of treatment-related toxicities, especially neutropenia. Table 2 shows several well-described clinically actionable alleles in UGT1A1, with observed frequencies in various populations. The wild-type allele (UGT1A1*1) has six TA repeats, while the most common variant allele in Caucasians (UGT1A1*28) has seven TA repeats. Approximately 10% of European-descent populations are homozygous for the UGT1A1*28 allele (TA indel/UGT1A1 7/7), while an additional 40% are heterozygotes for this variant. The greater number of promoter region repeats has been shown to result in less transcription; thus, patients – particularly those who are homozygous for the UGT1A1*28 polymorphism (or the *37 allele which has eight TA repeats and is associated with African ancestry) have reduced SN-38 clearance.
and are at higher risk of hematologic toxicity including severe neutropenia as well as dose-dependent severe diarrhea when receiving irinotecan.\textsuperscript{5,6,30,32–34} Patients with the \textit{UGT1A1*36} allele have five TA repeats and are not at increased risk of toxicities.\textsuperscript{35} In addition to TA repeat variants, patients carrying the \textit{UGT1A1*6} (or 211G\textgreater A) polymorphism in Exon 1 of the gene (most commonly observed in individuals of Asian ancestry) also have reduced enzyme activity and SN-38 clearance, which is also associated with an increased risk of irinotecan-related toxicities including severe neutropenia and diarrhea.\textsuperscript{36–42} The Food and Drug Administration (FDA) product label in the United States recommends that a lower starting dose of irinotecan should be considered for patients with the \textit{UGT1A1*28/*28} genotype.\textsuperscript{43}

Despite a relatively large body of evidence demonstrating the feasibility, safety, and cost-effectiveness of PGx testing for \textit{DPYD} and \textit{UGT1A1}, and despite FDA label prescribing information regarding relevant PGx for each, prospective genotyping for \textit{DPYD} and \textit{UGT1A1} prior to the administration of fluoropyrimidines and irinotecan is essentially non-existent in the United States.\textsuperscript{16,17,33,47} For fluoropyrimidines, only very recently did the European Medicines Agency recommend routine upfront testing of DPD deficiency.\textsuperscript{48} We hypothesize that the lack of routine PGx testing in the United States is due to a perceived deficiency of prospective, randomized data, as well as a paucity of appropriate systems for obtaining and translating germline PGx information to oncology clinicians at the bedside.\textsuperscript{49,50} We seek to address these implementation barriers, as well as this important evidence gap, with the design of the prospective, randomized PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care.

### Methods

#### Design

This is a randomized, prospective study to evaluate the effects of PGx testing on chemotherapy dosing decisions and on reducing medication-related adverse events in oncology patients. Patients with cancer who are planned to receive fluoropyrimidine (5-FU, capecitabine) and/or irinotecan therapy will be enrolled and randomly allocated to PGx and control arms (Figure 1). In the PGx arm, providers will be given immediate access to patient-specific information and

| \textit{DPYD} allele | Activity score\textsuperscript{1} | African ancestry, allele frequency | Caucasian\textsuperscript{2} ancestry, allele frequency | Other\textsuperscript{3} ancestry allele frequency | References |
|---------------------|-------------------------------|---------------------------------|---------------------------------|---------------------------------|------------|
| *2A \text{c.1905+1G\textgreater A rs3918290} | 0 | 0.0006–0.008 | 0.0079–0.022 | 0.0008–0.0051 | Deenen \textit{et al.}\textsuperscript{16} Henricks \textit{et al.}\textsuperscript{17} Amstutz \textit{et al.}\textsuperscript{18} ARUP Laboratories.\textsuperscript{19} |
| *13 \text{c.1679T\textgreater G p.I560S rs55886062} | 0 | 0 | 0.0006–0.01 | 0 | Deenen \textit{et al.}\textsuperscript{16} Henricks \textit{et al.}\textsuperscript{17} Amstutz \textit{et al.}\textsuperscript{18} ARUP Laboratories\textsuperscript{19} |
| \text{c.2846A\textgreater T p.D949V rs67376798} | 0.5 | 0.0006–0.008 | 0.0037–0.014 | 0.0006–0.0021 | Deenen \textit{et al.}\textsuperscript{16} Henricks \textit{et al.}\textsuperscript{17} Amstutz \textit{et al.}\textsuperscript{18} |
| \text{HapB3 c.1236G\textgreater A rs56038477} | 0.5 | 0.0031 | 0.0237 | 0.0059 | Deenen \textit{et al.}\textsuperscript{16} Henricks \textit{et al.}\textsuperscript{17} Amstutz \textit{et al.}\textsuperscript{18} |
| \text{p.Y186C c.557A\textgreater G rs115232898} | 0.5 | 0.016–0.0251 | 0.0001 | 0.0013 | Amstutz \textit{et al.}\textsuperscript{18} Elraiyah \textit{et al.}\textsuperscript{20} Offer \textit{et al.}\textsuperscript{21} |

\textsuperscript{1}Enzyme activity is defined as 1 = normal function, 0.5 = reduced function, 0 = no function. An individual’s activity score is defined as the sum of the two diploid alleles’ variant activity scores.

\textsuperscript{2}Caucasian ancestry cohort includes European and European-descent North American populations.

\textsuperscript{3}Other ancestry cohort includes Asian (East, South), Indian, Middle Eastern, and Americas populations.
Table 2. Selected actionable UGT1A1 variants, with associated functional implications and expected frequencies by ethnicity.

| UGT1A1 allele | Allele function | African ancestry, allele frequency | Caucasian ancestry, allele frequency | Other ancestry, allele frequency | References |
|---------------|-----------------|-----------------------------------|-------------------------------------|-------------------------------|------------|
| *36 5 TA repeats | Normal function | 0.08 | 0.0 | 0.0 | Dean35, Maeda et al.39, CPIC44, Gammal et al.45 |
| *6 211G>A rs4148323 | Reduced function | 0.001–0.004 | 0.007–0.01 | 0.0079–0.17 | Maeda et al.39, Onoue et al.41, CPIC44, Gammal et al.45 |
| *28 7 TA repeats | Reduced function | 0.3734 | 0.3165 | 0.1480–0.4142 | Innocenti et al.36, Maeda et al.39, CPIC44, Gammal et al.45, Iyer et al.44 |
| *37 8 TA repeats | Reduced function | 0.0570 | 0.0007–0.001 | 0.0043 | Dean35, Maeda et al.39, CPIC44, Gammal et al.45 |

1Caucasian ancestry cohort includes European and European-descent North American populations.
2Other ancestry cohort includes Asian (East, South), Indian, Middle Eastern, and Americas populations.

Figure 1. The ‘PhOCus Trial’ study design.

Patients with oncologic malignancies for whom fluoropyrimidine and/or irinotecan-inclusive therapy is being planned will be enrolled and randomly assigned to pharmacogenomic (PGx) and control arms, stratified by disease type and setting. In the PGx arm, subjects will be preemptively tested prior to oncology treatment initiation using a panel of PGx variants that may inform medication use/dosing. Providers will be given access to patient-specific information and genotypic dosing guidance in the form of the interactive software tool, Genomic Prescribing System (GPS). In the control arm, initial chemotherapy prescribing will occur as per standard of care (without the availability of genotype information). The co-primary endpoints are the comparison of dose intensity deviation rate (the proportion of subjects receiving modifications) during the first treatment cycle, and the incidence of grade 3 or higher toxicities throughout the treatment course. Secondary endpoints include cumulative chemotherapy dose intensity and anti-tumor efficacy measured by response rate, progression-free survival, and overall survival. Exploratory objectives will include the use of GPS to guide prescribing of other oncology-related and supportive medications, patient-reported quality of life, and patient understanding of PGx.
genotypic dosing guidance (based on patient DPYD and UGT1A1 variant allele status) in the form of the electronic medical record (EMR)-integrated software tool, the Genomic Prescribing System (GPS). In the control arm, initial fluoropyrimidine and irinotecan dosing will occur as per standard of care, and subject genotyping will be deferred until approximately 6 months after enrollment (after the course of chemotherapy).

The co-primary endpoints are dose intensity deviation rate (the proportion of patients receiving dose modifications) during the first treatment cycle, and the incidence of grade 3 or higher toxicities throughout the entire treatment course. Secondary endpoints will include overall chemotherapy dose intensity and key oncologic efficacy endpoints including response rate, progression-free survival (PFS), and overall survival (OS). Exploratory endpoints will include the impact of PGx on prescribing of additional PGx-informed oncology-related and supportive care medications, patient-reported quality of life, and patient understanding of PGx. We hypothesize that if oncology clinicians are provided preemptive PGx information to help guide fluoropyrimidine and irinotecan dosing, they will dose-modify treatments in an effort to mitigate and avoid toxicities, which may improve treatment tolerability as well as outcomes for cancer patients.

**Subjects**

Adult oncology patients (18 years or more) receiving care at the University of Chicago Comprehensive Cancer Center, and for whom treatment with a fluoropyrimidine and/or irinotecan treatment-containing regimen is being considered, are eligible. Specifically, enrollment will occur in breast, gastrointestinal (GI), and head and neck medical oncology clinics, given the common utilization of these agents in standard of care treatment. Recruitment will occur from across each of two physical cancer centers locations, including the university campus main medical center in Chicago, and a university-affiliated community-based oncology practice network site in suburban Chicago. Patients will be treatment-naïve for the planned chemotherapy agent of interest. Subjects will be approached for enrollment by the research coordinator in conjunction with standard of care oncology visits. Exclusion criteria include: (a) prior exposure to the planned chemotherapy of interest (fluoropyrimidine and/or irinotecan); (b) enrollment in another investigational trial which would preclude dose modifications of fluoropyrimidine and/or irinotecan chemotherapies; (c) history of or active consideration for bone marrow, liver, or kidney transplantation; (d) history of or active blood cancer (e.g. leukemia); (e) chronic kidney disease, as defined by estimated glomerular filtration rate (eGFR) <30/ ml/min/1.73 m², due to the risk of decreased drug excretion; and (f) liver dysfunction, as defined by the following laboratory values, due to the risk of decreased drug metabolism: total bilirubin ≥1.5 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥2.5 × upper limit of normal (AST and ALT ≥5 × upper limit of normal if hepatic metastases are present).

**Genotyping**

At enrollment, all patients will provide a blood sample for PGx germline genotyping. Genotyping will be carried out in a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory at the University of Chicago. The anticipated test turnaround time is 7–10 business days. All patients in the study will give consent to genotyping across our established custom panel of germline variants identified as affecting drug disposition, response, or toxicity (using OpenArray technology from Thermofisher). Patients will be genotyped specifically for five actionable variants within DPYD (Table 1). In an exploratory fashion, patients will also be genotyped for several previously implicated variants in the genes encoding for thymidylate synthase and thymidylate phosphorylase, although the genotype results for these variants will not be delivered clinically. For UGT1A1, the UGT1A1*6 exon variant will be assessed by OpenArray, while promoter sequence thymine-adenine-thymine-adenine (TATA) polymorphisms (UGT1A1*28, *36 and *37) will be assessed by a separate assay using polymerase chain reaction (PCR) and sizing by polyacrylamide gel (Table 2). To guide the potential use of supportive care medications (exploratory endpoint) separately, we will also genotype patients across our custom dedicated CYP2D6 panel, which uses the Invader technology from Hologic, complemented by CYP2D6 copy number assessment.

**Translation of genotype results and clinical decision support via the genomic prescribing system**

Multiple genomic profiling assays based on next-generation sequencing (NGS) are utilized...
The GPS is an interactive software tool that is linked to our institutional EMR that will provide oncology clinicians with subjects’ pharmacogenomics (PGx) results, prescribing recommendations, a list of alternative medications, as well as literature references and a level of evidence of each recommendation. Each summary utilizes traffic light iconography to allow clinicians rapidly to identify patient-specific recommendations: green ‘favorable’ lights, yellow ‘caution’ and red ‘warning’.

**Figure 2.** Pharmacogenomic clinical decision support provided via electronic medical record (EMR) embedded genomic prescribing system (GPS).

The GPS is an interactive software tool linked to the institutional EMR that will provide oncology clinicians with subjects’ pharmacogenomics (PGx) results, prescribing recommendations, a list of alternative medications, as well as literature references and a level of evidence of each recommendation. Each summary utilizes traffic light iconography to allow clinicians rapidly to identify patient-specific recommendations: green ‘favorable’ lights, yellow ‘caution’ and red ‘warning’.

Assessments

In addition to general demographic and clinical data, a research database will be created, which will record identifying information for each subject, including tumor type and stage, age, gender, height, weight, date of sample collection, and PGx results. Subjects’ medical records will be reviewed by research staff on a continual basis at 8–12 week time points while enrolled, and the database will be populated to include:

- **Oncology data:** Tumor type, histology, and stage, as well as the location of metastases, if applicable, will be documented at the
Table 3. Recommended dosing modifications according to DPD metabolizer status.

| Metabolizer category                  | Activity score | Recommended dose modification                                                                                                                                                                                                                                                                                                                                                     | References                                                                                                                                 |
|---------------------------------------|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Normal metabolizer                    | $1 + 1 = 2$     | This patient has a genotype in the DPYD drug-metabolizing gene that results in a normal rate of elimination of 5-fluorouracil and capecitabine. This is associated with the lowest risk of toxicity for patients receiving 5-fluorouracil or capecitabine, either alone or with other anticancer agents. Standard dosing is recommended. This recommendation is consistent with published guidelines by the Clinical Pharmacogenetics Implementation Consortium. | Deenen et al.\textsuperscript{14} Henricks et al.\textsuperscript{17} Amstutz et al.\textsuperscript{18} |
| Intermediate metabolizer—special scenario | $1 + 0.5 = 1.5$ | This patient has a genotype in the DPYD drug-metabolizing gene that results in a decreased rate of elimination of 5-fluorouracil and capecitabine. This is associated with an increased risk of severe or even life-threatening or fatal toxicity for patients receiving 5-fluorouracil or capecitabine at standard doses. The starting dose of the fluoropyrimidine should be reduced by 50%. Patients should be closely monitored for toxicity, with titration of the fluoropyrimidine dose as clinically indicated. This recommendation is in agreement with the FDA label guidance for capecitabine and 5-fluorouracil and is consistent with guidelines issued by the Clinical Pharmacogenetics Implementation Consortium. | Deenen et al.\textsuperscript{14} Henricks et al.\textsuperscript{17} Amstutz et al.\textsuperscript{18} Elraiyah et al.\textsuperscript{20} Offer et al.\textsuperscript{21} Boisdron-Celle et al.\textsuperscript{24} DailyMed\textsuperscript{58,59} |
| Intermediate metabolizer—standard CPIC | $1 + 0 = 1$     | This patient has a genotype in the DPYD drug-metabolizing gene that results in a decreased rate of elimination of 5-fluorouracil and capecitabine. This is associated with an increased risk of severe or even life-threatening or fatal toxicity for patients receiving 5-fluorouracil or capecitabine at standard doses. The starting dose of the fluoropyrimidine should be reduced by 50%. Patients should be closely monitored for toxicity, with titration of the fluoropyrimidine dose as clinically indicated. This recommendation is in agreement with the FDA label guidance for capecitabine and 5-fluorouracil and is consistent with published guidelines by the Clinical Pharmacogenetics Implementation Consortium. | Deenen et al.\textsuperscript{14} Henricks et al.\textsuperscript{17} Amstutz et al.\textsuperscript{18} Boisdron-Celle et al.\textsuperscript{24} DailyMed\textsuperscript{58,59} |
| Intermediate metabolizer—high risk    | $0.5 + 0.5 = 1$ | This patient has a genotype in the DPYD drug-metabolizing gene that results in a significantly decreased rate of elimination of 5-fluorouracil and capecitabine. This is associated with a significantly increased risk of severe or even life-threatening or fatal toxicity for patients receiving 5-fluorouracil or capecitabine at standard doses. The starting dose of the fluoropyrimidine should be reduced by at least 50%, and in some patients, an even greater dose-reduction is necessary. Patients should be monitored closely for toxicity, and further dose modifications may be necessary. If clinically possible, alternative chemotherapy agents could be considered. This recommendation is in agreement with FDA label guidance for capecitabine and 5-fluorouracil and is consistent with recommendations from the Clinical Pharmacogenetics Implementation Consortium. | Deenen et al.\textsuperscript{14} Henricks et al.\textsuperscript{17} Amstutz et al.\textsuperscript{18} Elraiyah et al.\textsuperscript{20} Offer et al.\textsuperscript{21} Boisdron-Celle et al.\textsuperscript{24} DailyMed\textsuperscript{58,59} |
| Poor metabolizer—Low function        | $0.5 + 0 = 0.5$ | This patient has a genotype in the DPYD drug-metabolizing gene that results in a markedly decreased rate of elimination of 5-fluorouracil and capecitabine. This is associated with a very high risk of life-threatening or fatal toxicity for patients receiving 5-fluorouracil or capecitabine. Fluoropyrimidines should be avoided, and alternative agents should be utilized if at all clinically possible. In the event that alternative agents are not considered a suitable therapeutic option, fluoropyrimidines should be administered at a strongly reduced dose (≤25% of the normal starting dose) with early therapeutic drug monitoring. This recommendation is consistent with published guidelines from the Clinical Pharmacogenetics Implementation Consortium. | Deenen et al.\textsuperscript{14} Henricks et al.\textsuperscript{17} Amstutz et al.\textsuperscript{18} Elraiyah et al.\textsuperscript{20} Offer et al.\textsuperscript{21} Boisdron-Celle et al.\textsuperscript{24} DailyMed\textsuperscript{58,59} |
| Poor metabolizer—No function         | $0 + 0 = 0$     | This patient has a genotype in the DPYD drug-metabolizing gene that results in absent elimination of 5-fluorouracil and capecitabine. This is associated with a very high risk of life-threatening or fatal toxicity for patients receiving 5-fluorouracil or capecitabine. Fluoropyrimidine use should be avoided. The use of alternative agents is recommended. If there is no alternative agent available, a clinical pharmacology consultation is recommended. This recommendation is in agreement with FDA label guidance for capecitabine and 5-fluorouracil and is consistent with published guidelines from the Clinical Pharmacogenetics Implementation Consortium. | Deenen et al.\textsuperscript{14} Henricks et al.\textsuperscript{17} Amstutz et al.\textsuperscript{18} Boisdron-Celle et al.\textsuperscript{24} DailyMed\textsuperscript{58,59} |
## Table 4. Recommended dosing modifications according to UGT1A1 metabolizer status.

| Phenotype        | Diploftype                          | Recommended dose modification                                                                                                                                                                                                 | References               |
|------------------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Extensive        | Homozygous *1, *36 or *1/*36        | This patient has a genotype in the *UGT1A1* drug-metabolizing gene that results in a higher rate of elimination of SN-38, the active metabolite of irinotecan. This is associated with the lowest risk of toxicity for patients receiving irinotecan, either alone or in combination with other anticancer agents. Standard dosing of irinotecan is recommended. There is less well-established evidence that patients with this genotype may tolerate higher than standard doses of irinotecan, particularly in the context of monotherapy or within the FOLFIRI regimen. However, it is not known whether or not the administration of higher doses is more effective than standard doses. The above is consistent with published guideline recommendations from the Royal Dutch Pharmacists Association Pharmacogenetics Working Group and is in agreement with the Food and Drug Administration label for irinotecan. | Innocenti et al., Sharma et al., Toffoli et al., Tsai et al., CPIC, Catenacci et al. |
| Intermediate     | Heterozygous *28, *37, *6 with any of the above variants | This patient has a genotype in the *UGT1A1* drug-metabolizing gene that results in a typical (but lower than extensive metabolizers) rate of elimination of SN-38, the active metabolite of irinotecan, classifying them as an intermediate metabolizer. In these patients, SN-38 clearance is approximately 75% compared to extensive metabolizers. The risk of toxicity is likely linked to the irinotecan dose intensity. In the context of a two-drug regimen such as FOLFIRI, no initial dose modifications are recommended. In the setting of a three-drug regimen such as FOLFIRINOX, an initial starting irinotecan dose of 135 mg/m$^2$ is recommended, with further titration based on tolerability. The above recommended dosing is based on seven studies demonstrating tolerability in 193 patients with gastrointestinal malignancies treated with two and three-drug combination irinotecan-containing chemotherapy regimens. | Innocenti et al., Shirasu et al., CPIC, Catenacci et al., Sharma et al., Toffoli et al., Tsai et al., Páez et al. |
| Poor             | Homozygous *28, *37, *6, or heterozygous combinations of any of these high-risk variants | This patient has a genotype in the *UGT1A1* drug-metabolizing gene that results in a much lower rate of elimination of SN-38, the active metabolite of irinotecan, classifying them as a poor metabolizer. In these patients, SN-38 clearance is approximately 50% compared to extensive metabolizers. This is associated with an increased risk of irinotecan toxicity, either alone or in combination with other anticancer agents. The risk for toxicity is likely linked to the dose intensity of irinotecan. In the context of a two-drug regimen such as FOLFIRI, a starting dose of 135 mg/m$^2$ followed by titration based on tolerability is recommended. In the setting of a three-drug regimen such as with FOLFIRINOX, a starting dose of 90 mg/m$^2$ is recommended with titration based on tolerability. The above is consistent with published guideline recommendations from the Royal Dutch Pharmacists Association Pharmacogenetics Working Group and is in agreement with the Food and Drug Administration label for irinotecan. | Innocenti et al., Shirasu et al., CPIC, Sharma et al., Tsai et al. |
time of enrollment. In addition, anticancer treatment details, including disease setting and treatment modalities, will be recorded.

- **Laboratory assessments:** Standard laboratory tests obtained as part of routine care, including biochemistry (renal and hepatic function) as well as complete blood count, and tumor markers, if available, will be documented.

- **Medication list:** A baseline medication list will be created by the study team at enrollment. Any additions, dose changes, drug discontinuations with dates subsequent to the time of enrollment will be documented. Chemotherapy dosing, schedule (including dose frequency), as well as dose delays, will be recorded.

- **Adverse complications and events:** All adverse events and toxicities experienced by enrolled subjects will be recorded, with dates, and will be updated on a continual basis for each subject whenever they present for medical attention. Toxicities may be revealed by the study team’s review of the medical record, notification of the study team by a participating subject or their provider, or through query of an enrolled subject via surveys administered every 8–12 weeks. Adverse events will be analyzed by the study team to determine if the adverse event in question was ‘potentially impacted’ by genetic variants that were tested.

- **Oncologic outcomes:** Response rate, PFS, and OS will be tracked. To assess PFS and response rate, the study team will review progress notes by the treatment team along with radiologic assessments for confirmation of disease status, tumor response, and to enable the capture of subsequent changes in therapy. Progressive disease will be defined as provider documentation of disease progression or disease-related death. Assessment of PFS, OS, and response rate will be performed stratified by disease type as well as treatment setting (adjuvant, metastatic, etc.), and compared between arms and to historical controls treated per standard of care.

**Endpoints**

The co-primary endpoints are: (a) dose intensity deviation rate (the proportion of patients receiving modifications) during the first treatment cycle; and (b) the incidence of grade 3 or higher toxicities throughout the entire treatment course. Secondary endpoints will include: (a) overall chemotherapy dose intensity; and (b) progression-free survival (plus response rate and overall survival, as available). Exploratory endpoints will include: (a) the impact of PGx on prescribing of additional PGx-informed oncology related and supportive care medications; (b) patient-reported quality of life (QOL); and (c) patient understanding of PGx.

**Chemotherapy dose determination**

Each dose and date of chemotherapy administration will be recorded. Standard of care dosing will be defined by the signed chemotherapy plan, in which the dose is specified by the University of Chicago Chemotherapy Pharmacy Improvement Team based on tumor-specific National Comprehensive Care Network (NCCN) guidelines. Chemotherapy doses that deviate from this standard dosing will be calculated and compared between patients in both the PGx and control arms. The reasons for dose deviation, if available, will be documented.

**Chemotherapy toxicity assessment**

While the subject remains enrolled, clinicians will be asked to document toxicity occurrences, graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.064 in each progress note. Only ADEs thought attributable [with attribution score of 3 (possible), 4 (probable), or 5 (definite)] to fluoropyrimidine and/or irinotecan administration will be included in the primary endpoint analysis of the incidence of ⩾ grade 3 toxicities. For subjects receiving fluoropyrimidines, the following ADEs will be attributed as likely related to this agent’s administration (in the absence of another obvious cause) and graded as per Supplemental
Table 1: neutropenia, diarrhea, hand-foot syndrome and mucositis (n.b.: the latter will be excluded as a primary fluoropyrimidine-related ADE in head and neck cancer patients receiving concomitant radiation therapy). For subjects receiving irinotecan, the following ADEs will be attributed as likely related to this agent’s administration (in the absence of another obvious cause) and graded as per Supplemental Table 2: neutropenia and diarrhea. Any ambiguous grade 3 or higher toxicity possibly related to either agent will be adjudicated by a panel of study reviewers who are blinded to treatment arm. Adverse events related to other chemotherapy or anti-cancer agents, from radiation therapy or from the underlying disease process, will be recorded in the database but will not be attributed or included in the primary analysis. Toxicity assessments will occur weekly during cycle 1 of chemotherapy, and on an ongoing basis at intervals of at least every 8–12 weeks while the subject remains on study. At the end of the study, a composite toxicity rate of ≥ grade 3 adverse events will be calculated for both PGx and control arms.

**Longitudinal survey results**

At routine clinic visits with their oncology provider, we will assess subject views about the visit and about any treatment decisions that were made. These assessments will occur through the administration of a questionnaire by research staff at or immediately after the first visit, and at an interval of at least every 8–12 weeks while the subject remains enrolled. The questionnaires will query QOL, treatment decision-making, patient–provider interactions, the provider–patient relationship, and subject satisfaction with care to determine if there are differences between the two groups in these measures.57,65–67

**Standard protocol approval, registration, and patient consent**

The project was approved by both the Clinical Trials Review Committee (CTRC) and the institutional review board (IRB) at the University of Chicago Medical Center as of 14 August 2020. It is registered at ClinicalTrials.gov (#NCT04541381). Every enrolled patient will provide written informed consent. Patients may withdraw from the study at any time without affecting their current or future care.

**Duration of participant follow-up and subject withdrawal**

Enrolled subjects will be followed for the duration of time they remain on fluoropyrimidine and/or irinotecan therapy, and for at least 1 month following chemotherapy completion to document treatment-related adverse events. Efficacy endpoints beyond this dedicated observation period will also be captured (e.g. PFS/OS). Subjects on maintenance chemotherapy will be followed for toxicity endpoints up to 6 months. Subjects may withdraw from the study at any time, and participation may be discontinued if they are lost to follow-up, the study is terminated, or the investigator feels that it is no longer in the subject’s best interest to participate.

**Statistics**

Upon enrollment subjects will be randomly allocated to an upfront genotyping or ‘PGx-guided’ arm versus a control arm. Timing of genotyping is determined by randomized assignment to either of these two groups. Randomization schema will be stratified by cancer type (breast, GI, head and neck), disease-specific stage, and treatment setting (adjuvant vs. metastatic, including line of metastatic therapy within this latter setting). Given institutional cancer-type volumes and strategic enrollment plans, we anticipate that half of all enrolled subjects will have GI malignancies, with the rest composed of patients with breast and head/neck malignancies. Based on prior institutional census data, we estimate that 75% of enrolled patients will be Caucasian (European/North American ancestry), and 25% will be of African ancestry. The study was powered based on the expected allele frequencies of *DPYD* and *UGT1A1* variants displayed in Tables 1 and 2, with an estimated composite prevalence of actionable variants by ethnicity expected to be 19.2% and 19.1% for African and European ethnicities, respectively. For half of all subjects enrolled (i.e. those with GI malignancies) PGx information related to both fluoropyrimidines and irinotecan are of interest. For the other half of the subjects with head/neck or breast malignancies, we anticipate only fluoropyrimidine-related PGx information will be clinically relevant, and dedicated *UGT1A1* testing will not be performed in these subjects. For these subjects, the estimated prevalence of variant alleles was based on *DPYD* only and is 4.7% and 3.2%, for European-descent and African-descent populations, respectively. Based on the above expected subject demographics and our disease clinic/cancer type enrollment plans, we estimate that for enrolled subjects of African ancestry, 11.2% of evaluable patients will carry an actionable variant affecting a chemotherapy of interest that they will receive. For subjects of European
ancestry, a similar estimated 11.9% of treated patients will have an actionable variant. Thus, the study is conservatively powered for an approximate 10% actionable variant allele prevalence across all enrolled subjects.

In the first stage of the study, enrolled patients will be randomly assigned to PGx versus control arms in a 3:1 ratio to enrich the PGx arm for analysis of co-primary endpoint 1 (Figure 3). For co-primary endpoint 1, the dose intensity deviation rate \( P_{dev} \) (defined as the proportion of patients receiving cycle 1 dose modifications) will be measured for both arms. We assume dose intensity deviation rates of 10% in the control arm due to other clinical factors (e.g., fragility, performance status), an estimate based on historical evidence. For the PGx arm, we expect most clinicians proactively to dose reduce patients carrying risk alleles; thus, we conservatively estimate 50% dose modification rates (i.e., 50% concordance with PGx guidance) in individuals with at-risk variant alleles. Stage 1 randomization will be performed in a 3:1 ratio so that analysis is powered to detect a dose deviation difference, \( P_{dev} \). Dosing deviation (\( P_{dev} \)) will be calculated and compared between patients with risk alleles in the PGx arm versus all patients in the control arm for the first cycle of chemotherapy. As a secondary analysis, we will examine whether clinicians’ decisions on dose modification correlates with any of the demographic or clinical variables of interest, including age, gender, ethnicity, cancer type or stage, and at-risk allele status.

After the accrual of 160 patients (120 in the PGx arm, 40 in the control arm; defined as the end of stage 1), enrollment will be halted, and an interim analysis will be performed to confirm that the expected variant allele frequency rates have been observed. If no meaningful difference is detected between the observed and expected frequencies, then the risk considerations will be deemed not to
have changed for subsequent subjects, and the study will proceed to enrollment of the remaining patients.

In stage 2, patients will be randomly assigned to PGx vs. control arms in a 1.8:1 ratio, for evaluation of the second co-primary endpoint, $P_{\text{tox}}$ (toxicity rate of grade 3 or higher adverse events). The sample size calculation for co-primary endpoint 2 of the study is based on the expected incidence of grade 3 or higher toxicity rate among patients with the at-risk allele versus wild-type (WT), as established in prior literature ($P_{\text{tox}}$ of 70% and 30%, respectively). The primary analysis will be performed comparing toxicity rates between group 1 (variant allele carriers in control arm) and group 3 (variant allele carriers in PGx arm). Logistic regression analysis will also be performed to evaluate the association between the incidence of adverse events with variables of interest such as age, gender, ethnicity, cancer type, at-risk allele status, study arm, and chemotherapy dosing intensity (standard of care or modified dosing). If patients are genotyped via alternative means, or in the case that genotyping results are not available at the time of treatment initiation, patients will be analyzed on an intent-to-treat basis.

Secondary endpoints will be analyzed as follows:

- At the conclusion of the study, the cumulative chemotherapy drug dose intensity (the function of dose and frequency of drug administration) received by each subject during the entire treatment course will be calculated.
- Response and survival assessments will be analyzed, including response rate, PFS, and OS. These endpoints will be analyzed by tumor type, stage, and disease setting, and will be compared between arms and within each arm compared to historical controls treated per standard of care.

Exploratory endpoints will be analyzed as follows:

- Many medications commonly utilized in oncologic patients have well established PGx guidance and have been included in the GPS. Patient-specific information and dosing recommendations for these medications will be available to clinicians along with their genotyping results through GPS access.
- Subject-reported QOL and understanding of PGx will be captured by survey instruments administered to subjects in both arms at enrollment, weekly during cycle 1, and on an ongoing basis of 8–12 week intervals while the patient remains on study.

Potential benefit for participants
All participants will receive PGx testing that could aid their clinicians in prescribing decisions for chemotherapy, and other PGx informed medications. This could potentially permit the avoidance of medications, or doses, which might be harmful to the subject, or alternatively, it might allow the identification of subjects as particularly likely to benefit from a given drug or therapy.

Potential risks and burdens for participants
The primary potential risks of participation are those associated with potential adverse outcomes to subjects if providers make medication or chemotherapy dosing changes that are based on subject-specific PGx findings that result in harm and/or altered anti-tumor efficacy; however, anti-tumor efficacy is thought to be preserved given prior literature demonstrating similar toxicity rates and pharmacokinetic parameters in patients carrying variant alleles receiving dose modifications.

Secondly, only select variants of $\text{DPYD}$ and $\text{UGT1A1}$ (Tables 1 and 2) for which published studies demonstrating their PGx relevance will be tested. Chemotherapy drug metabolism, efficacy, and risk of toxicity may be affected by additional genetic factors that will not be evaluated. Thus, despite preemptive dose modifications, patients may develop toxicities due to other factors.

Conclusion
Chemotherapies such as fluoropyrimidines and irinotecan have well-known germline PGx associations. Preemptive genotyping offers the potential to identify individuals at increased risk of ADEs and improve patient outcomes. Our project seeks to demonstrate the potential benefit of utilizing preemptive PGx testing to provide individualized chemotherapy dosing. To our knowledge, this study will be the first of its kind to implement broad preemptive PGx information, in a prospective randomized fashion, across the oncology care setting (that is, for multiple malignancies). Providing this platform of integrated germline PGx information may enable personalized chemotherapy dosing decisions and establish a new model of care, incorporating comprehensive genomic data to optimize oncology treatment.
planning. This may improve tolerability and outcomes for cancer patients receiving commonly prescribed chemotherapies.

Conflict of interest statement
M.J. Ratain is a coinventor holding patents related to pharmacogenetic diagnostics and receives royalties related to UGT1A1 genotyping.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics T32 training grant NIH 5T32GM007019-41 (N. Reizine as a trainee) and the Benjamin McAllister Research Fellowship Award (N. Reizine as a trainee).

ORCID ID
Natalie Reizine https://orcid.org/0000-0001-9240-9943

Supplemental material
Supplemental material for this article is available online.

References
1. Pearce A, Haas M, Viney R, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: a prospective cohort study. PLoS One 2017; 12: e0184360.
2. Rashid N, Koh HA, Baca HC, et al. Clinical impact of chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. J Manag Care Spec Pharm 2015; 21: 863–871.
3. Hardy D, Cormier JN, Xing Y, et al. Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer. J Thorac Oncol 2010; 5: 90–98.
4. Relling MV, Pui CH, Cheng C, et al. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006; 107: 843–844.
5. Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99: 1290–1295.
6. Hu Z-Y, Yu Q and Zhao Y-S. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur J Cancer 2010; 46: 1856–1865.
7. Etienne-Grimaldi MC, Boyer JC, Beroud C, et al. New advances in DPYD genotype and risk of severe toxicity under capcitabine. PLoS One 2017; 12: e0175998.
8. Ezzeldin H and Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004; 4: 181–189.
9. Cavallari LH and Weitzel K. Pharmacogenomics in cardiology – genetics and drug response: 10 years of progress. Future Cardiol 2015; 11: 281–286.
10. Sorrentino MJ and O’Donnell PH. Pharmacogenomics and cardiology: improving treatment with existing drugs. Pharmacogenomics 2015; 16: 1223–1226.
11. Cheng HH, Sokolova AO, Schaeffer EM, et al. Germline and somatic mutations in prostate cancer for the clinician. J Natl Compr Canc Netw 2019; 17: 515–521.
12. Litton JK, Burstein HJ and Turner NC. Molecular testing in breast cancer. Am Soc Clin Oncol Educ Book 2019; 39: e1–e7.
13. Stricker T, Catenacci DV and Seiwert TY. Molecular profiling of cancer – the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol 2011; 38: 173–185.
14. O’Donnell PH and Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol 2012; 6: 251–259.
15. Thorn CF, Marsh S, Carrillo MW, et al. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 2011; 21: 237–242.
16. Deenen MJ, Meulendijks D, Cats A, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 2016; 34: 227–234.
17. Henricks LM, Lunenburg C, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018; 19: 1459–1467.
18. Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 2018; 103: 210–216.
19. ARUP Laboratories. *Dihydropyrimidine dehydrogenase (DPYD) testing*, 2020. https://ltd.aruplab.com Tests/Pub/2012166 (accessed 7 November 2020).

20. Elraiyah T, Jerde CR, Shrestha S, et al. Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population. *Clin Pharmacol Ther* 2017; 101: 382–390.

21. Offer SM, Lee AM, MattisonLK, et al. A DPYD variant (Y186C) in individuals of African ancestry is associated with reduced DPD enzyme activity. *Clin Pharmacol Ther* 2013; 94: 158–166.

22. Boige V, Vincent M, Alexandre P, et al. DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial. *JAMA Oncol* 2016; 2: 655–662.

23. Henricks LM, van Merendonk LN, Meulendijks D, et al. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: a matched pair analysis. *Int J Cancer* 2019; 144: 2347–2354.

24. Boisdron-Celle M, Capitain O, Faroux R, et al. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach. *Semin Oncol* 2017; 44: 13–23.

25. Launay M, Ciccolini J, Fournel C, et al. Upfront DPD deficiency detection to secure 5-FU administration: part 2- application to head-and-neck cancer patients. *Clin Cancer Drugs* 2017; 15: 295–301.

26. ClinicalTrials.gov. Improving the safety of fluoropyrimidine-based chemotherapy (Alpe2U), 2020. https://clinicaltrials.gov/ct2/show/NCT041 94957?cond=dpyd&draw=2&rank=5 (accessed 7 November 2020).

27. ClinicalTrials.gov. Association of Dihydropyrimidine Dehydrogenase (DPYD) variants with toxicity related to capecitabine, 2020. https://clinicaltrials.gov/ct2/show/NCT00478686?cond=dpyd&draw=2&rank=2 (accessed 7 November 2020).

28. ClinicalTrials.gov. Predicting response to capecitabine in women with metastatic breast cancer, 2020. https://clinicaltrials.gov/ct2/show/NCT009 53537?cond=dpyd&draw=2&rank=9 (accessed 7 November 2020).

29. Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. *Cancer Res* 1991; 51: 4187–4191.

30. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. *Cancer Res* 2000; 60: 6921–6926.

31. Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. *Clin Pharmacol Ther* 2004; 75: 501–515.

32. Rouits E, Boisdron-Celle M, Dumont A, et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. *Clin Cancer Res* 2004; 10: 5151–5159.

33. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. *J Clin Oncol* 2004; 22: 1382–1388.

34. Marcuello E, Altès A, Menoyo A, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. *Br J Cancer* 2004; 91: 678–682.

35. Dean L. Irinotecan therapy and UGT1A1 genotype. In: Pratt VM, McLeod HL, Rubinstein WS, et al. (eds) *Medical Genetics Summaries*. Bethesda, MD: National Center for Biotechnology Information, 2012.

36. Innocenti F, Liu W, Chen P, et al. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. *Pharmacogenet Genomics* 2005; 15: 295–301.

37. Yang Y, Zhou M, Hu M, et al. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: a meta-analysis. *Asia Pac J Clin Oncol* 2018; 14: e479–e489.

38. Han FF, Guo CL, Yu D, et al. Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. *Cancer Chemother Pharmacol* 2014; 73: 779–788.

39. Maeda H, Hazama S, Shavkat A, et al. Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations. *Mol Diagn Ther* 2014; 18: 333–342.

40. Zhou CF, Ma T, Su Y, et al. UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. *Anticancer Agents Med Chem* 2013; 13: 235–241.
41. Onoue M, Terada T, Kobayashi M, et al. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. *Int J Clin Oncol* 2009; 14: 136–142.

42. Shirasu H, Todaka A, Omae K, et al. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. *Cancer Sci* 2019; 110: 707–716.

43. DailyMed. *Label: Irinotecan hydrochloride – irinotecan hydrochloride injection, solution*, 2015. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ef76dc4-ab02-4a45-ab36-0a14ddf4ef (accessed 21 August 2019).

44. CPIC. *Guideline for atazanavir and UGT1A1*, 2015. https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/ (accessed 7 November 2020).

45. Gammal RS, Court MH, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. *Clin Pharmacol Ther* 2016; 99: 363–369.

46. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. *Pharmacogenomics J* 2002; 2: 43–47.

47. Catenacci DVT, Chase L, Lomnicki S, et al. Evaluation of the association of perioperative UGT1A1 genotype-dosed gFOLFIRINOX with margin-negative resection rates and pathologic response grades among patients with locally advanced gastroesophageal adenocarcinoma: a phase 2 clinical trial. *JAMA Netw Open* 2020; 3: e1921290.

48. European Medicines Agency. *EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine*, 2020. https://www.ema.europa.eu/en/news/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine (accessed 21 August 2019).

49. Freedman AN, Sansbury LB, Figg WD, et al. Cancer pharmacogenomics and pharmacoprevalence: setting a research agenda to accelerate translation. *J Natl Cancer Inst* 2010; 102: 1698–1705.

50. Wheeler HE, Maitland ML, Dolan ME, et al. Cancer pharmacogenomics: strategies and challenges. *Nat Rev Genet* 2013; 14: 23–34.

51. Danahey K, Borden BA, Furner B, et al. Simplifying the use of pharmacogenomics in clinical practice: building the genomic prescribing system. *J Biomed Inform* 2017; 75: 110–121.

52. Castro-Rojas CA, Esparza-Mota AR, Hernandez-Cabrera F, et al. Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer. *Drug Metab Pers Ther* 2017; 32: 209–218.

53. De Bruin M, Van Capel T, Smid K, et al. The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase. *Eur J Pharmacol* 2004; 491: 93–99.

54. Iyer L, Hall D, Das S, et al. Phenotype–genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. *Clin Pharmacol Ther* 1999; 65: 576–582.

55. Fang H, Liu X, Ramirez J, et al. Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. *Pharmacogenomics J* 2014; 14: 564–572.

56. Leung EKY, Agolini E, Pei X, et al. Validation of an extensive CYP2D6 assay panel based on invader and TaqMan copy number assays. *J Appl Lab Med* 2019; 1: 471–482.

57. O’Donnell PH, Bush A, Spitz J, et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. *Clin Pharmacol Ther* 2012; 92: 446–449.

58. DailyMed. *Label: Capecitabine – capecitabine tablet*, 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30830d24-1421-4c25-9b6b-c15705aa4357 (2019, accessed 21 August 2019).

59. DailyMed. *Label: Fluorouracil – fluorouracil injection, solution*, 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21af1777-87f7-4e40-9917-f1677e7ff1a5 (2017, accessed 21 August 2019).

60. Sharma MR, Joshi SS, Karrison TG, et al. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. *Cancer* 2019; 125: 1629–1636.

61. Toffoli G, Cecchin E, Gasparini G, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. *J Clin Oncol* 2010; 28: 866–871.

62. Tsai HL, Huang CW, Lin YW, et al. Determination of the UGT1A1 polymorphism
as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). *Eur J Cancer* 2020; 138: 19–29.

63. Páez D, Tobeña M, Fernández-Plana J, *et al.* Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. *Br J Cancer* 2019; 120: 190–195.

64. CTCAE. *Common terminology criteria for adverse events*, version 5, 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf (accessed 7 November 2020).

65. Osoba D, Rodrigues G, Myles J, *et al.* Interpreting the significance of changes in health-related quality-of-life scores. *J Clin Oncol* 1998; 16: 139–144.

66. O'Donnell PH, Danahey K, Jacobs M, *et al.* Adoption of a clinical pharmacogenomics implementation program during outpatient care – initial results of the University of Chicago “1,200 Patients Project”. *Am J Med Genet C Semin Med Genet* 2014; 166C: 68–75.

67. Truong TM, Apfelbaum J, Shahul S, *et al.* The ImPreSS trial: implementation of point-of-care pharmacogenomic decision support in perioperative care. *Clin Pharmacol Ther* 2019; 106: 1179–1183.

68. Launay-Vacher V, Chatelut E, Lichtman SM, *et al.* Renal insufficiency in elderly cancer patients: international society of geriatric oncology clinical practice recommendations. *Ann Oncol* 2007; 18: 1314–1321.

69. Garcia G and Odaimi M. Systemic combination chemotherapy in elderly pancreatic cancer: a review. *J Gastrointest Cancer* 2017; 48: 121–128.

70. Innocenti F, Schilsky RL, Ramirez J, *et al.* Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. *J Clin Oncol* 2014; 32: 2328–2334.